![Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business](https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2018/02/931/506/drugs-with-prescription-pad_large-f2815d7acd668510VgnVCM200000d6c1a8c0____-2.jpg?ve=1&tl=1)
Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business
![Teva Pharmaceuticals on Twitter: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press Teva Pharmaceuticals on Twitter: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press](https://pbs.twimg.com/media/FYn8FMIXoAMvgvr.jpg:large)
Teva Pharmaceuticals on Twitter: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press
![Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease - Huntington's Disease News Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease - Huntington's Disease News](https://www.newshd.net/wp-content/uploads/2016/09/TEVA.jpg)